“SGLT2 Inhibitors Relax Mesenteric Arteries via CGRP Release from Sensory Nerves Independent of Glucose Transport”

https://pubmed.ncbi.nlm.nih.gov/38116028

SGLT2 inhibitors, commonly used for blood glucose control and heart failure treatment, relax mesenteric arteries via a novel mechanism involving release of calcitonin gene-related peptide (CGRP) from sensory nerves, independent of glucose transport and subsequent to sodium/hydrogen exchanger (NHE1) inhibition.